Extension application is based on results from Janssen’s Route 6 study
News
Genentech’s Gavreto scores US approval for RET thyroid cancer
Precision therapy is designed to selectively target RET alterations
RPS in discussions with government to improve patient access to medicines
Follows joint letter calling for pharmacists to be able make minor prescription changes
Janssen eyes US approval for EGFR-targeting NSCLC therapy
Bispecific antibody targets EGFR and MET mutated tumours
PureTech launches phase II ‘long COVID’ drug trial
LYT-100 will be evaluated in patients with persistent symptoms caused by COVID-19
AbbVie partners with Frontier Medicines on protein degrader development
Partnership will seek to develop small molecules for oncology/immunology targets
Janssen buys rights to Hemera’s eye disease gene therapy candidate
Therapy targets CD59 protein to preserve vision in geographical atrophy patients
DSRU plans ‘post-authorisation’ study of COVID-19 vaccines in the UK
Drug Safety Research Unit set to conduct active surveillance study on COVID-19 vaccines
Bayer establishes new cell and gene therapy platform
Platform will enable Bayer to pursue external collaborations and bolster internal capabilities
Vectura, Kinaset Therapeutics set to develop inhaled asthma drug
Companies have signed development and commercialisation agreement
Roche’s Xolair gets US nod for nasal polyps treatment
IgE blocker approved as an add-on treatment for adult patients
Bayer inks deal with Blackford Analysis to develop radiology AI platform
Agreement will aim to develop a platform to support radiologists’ decision-making
UK approves Pfizer/BioNTech’s COVID-19 vaccine
First doses for emergency use will be delivered ‘immediately’
Patient Partnership Index 2020 Insights Report published
Follows on from success of the inaugural Patient Partnership Index Conference
AZ sells rights to statin med Crestor to Grünenthal
Grünenthal will pay $320m upfront for the rights
